Lilly’s Foundayo shows reduced diabetes, heart disease risk

Eli Lilly and Company's post-hoc analyses of its ATTAIN-1 trial have revealed promising results for its diabetes and cardiovascular disease risk-reducing medication, Foundayo. The Phase 3 trial, which involved 3,127 participants, demonstrated that Foundayo significantly reduced the predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with weight-related medical conditions.

At 72 weeks, participants taking the 17.2 mg dose of Foundayo showed a 57% reduction in predicted type 2 diabetes risk and an 18% reduction in predicted cardiovascular disease risk compared to placebo. Lower doses of Foundayo also showed reductions in predicted type 2 diabetes risk, with the 9 mg and 5.5 mg doses showing 50% and 45% reductions, respectively.

The findings were published in Diabetes, Obesity and Metabolism and were based on risk assessments using the Cardiometabolic Disease Staging risk engine for type 2 diabetes and the BMI-based Framingham risk engine for cardiovascular disease.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.